Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 5/20 | 0.43 |
| ▸ | EDNRB | P24530 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770903 | 0.87 | KEAP1 (0.40) | EDNRAEDNRBMAPTTP53TDP1 | |
| SCHEMBL6772985 | 0.84 | EDNRA (0.42) | EDNRAEDNRB | |
| SCHEMBL6777479 | 0.83 | EDNRB (0.44) | EDNRAEDNRB | |
| SCHEMBL6640093 | 0.82 | EDNRA (0.44) | EDNRAEDNRBMAPTTP53TDP1 | |
| SCHEMBL6772653 | 0.81 | NPSR1 (0.35) | EDNRAEDNRBMAPTTP53TDP1 | |
| SCHEMBL4632438 | 0.80 | MMP2 (0.37) | MAPTTP53KMT2AALDH1A1GAA | |
| SCHEMBL7086349 | 0.79 | TSHR (0.40) | EDNRATP53KMT2ANPSR1ALDH1A1 | |
| SCHEMBL6777059 | 0.78 | EDNRA (0.46) | EDNRA | |
| SCHEMBL6776271 | 0.78 | EDNRA (0.46) | EDNRA | |
| SCHEMBL4632118 | 0.77 | EDNRB (0.42) | EDNRAEDNRBMAPTTP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6271248-B1 | USED IN TREATING HYPERTENSION, PULMONARY HYPERTENSION, RENAL/ GLOMERULAR/MESANGIAL CELL DISORDERS, ENDOTOXEMIA, ISCHEMIA, TUMOR GROWTH, ATHERSCLEROSIS, RESTENOSIS, SUBARACHNOID HEMORRHAGE, PROSTATIC HYPERTROPHY, CONGESTIVE HEART FAILURE | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6080774-A | Substituted biphenylsulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0768305-A1 | N-Isoxazolyl-biphenylsulfonamide derivatives, their preparation and their use as endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |